{"id":62324,"date":"2026-06-09T08:31:19","date_gmt":"2026-06-08T23:31:19","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4582-20260609-01_wp_basic\/"},"modified":"2026-07-12T11:19:09","modified_gmt":"2026-07-12T02:19:09","slug":"4582-20260609-01_wp_basic","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/","title":{"rendered":"Completion of Patient Enrollment (FPI) in NIH-led Clinical Trial of IV BCV for Progressive Multifocal Leukoencephalopathy"},"content":{"rendered":"","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceuticals Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-09","jir_source_link":"[Placeholder]","jir_short_summary":"Under a CRADA led by NIH\/NINDS, the first patient enrollment for an IV BCV clinical trial targeting PML has been completed. The trial is conducted at the NIH Clinical Center in Bethesda, Maryland. No impact on the Full Year 2026 forecast. Continued development in the neurodegenerative disease area will be pursued.","jir_summary":"### Progress on business and projects\nSymBio Pharmaceuticals is advancing an IV BCV clinical trial for progressive multifocal leukoencephalopathy (PML) under the CRADA with NIH\/NINDS, and has completed enrollment of the first patient. The trial, conducted at the NIH Clinical Center in Bethesda, is being led by Dr. Irene Cortese to evaluate efficacy and safety. PML is a severe brain disease caused by JC virus, with no established standard treatment.\n\n### Strategy and outlook\nThe company is pursuing BCV across three areas: (1) Phase III trial in infectious diseases, (2) clinical preparation in hematologic and solid tumors, and (3) development in neurodegenerative diseases, running in parallel. Through the CRADA targeting PML and multiple sclerosis with NIH collaboration, the aim is to accumulate clinical evidence and achieve global expansion of BCV.","jir_financial_highlights":"Unknown: Unknown","jir_category":"Other","jir_hashtags":"#SymBioPharma, #IR, #JapaneseStocks","jir_key_figures":"Clinical trial start: Enrollment of first patient completed\nTarget disease: Progressive multifocal leukoencephalopathy (PML)\nAnnouncement date: 2026-06-09","jir_meta_title":"\u3010SymBio Pharmaceuticals\u3011First patient enrolled in IV BCV trial for PML\uff5cJune 2026","jir_meta_description":"SymBio Pharmaceuticals completed the first patient enrollment in the IV BCV clinical trial for PML under CRADA with NIH\/NINDS. The trial is now evaluating efficacy and safety at the NIH Clinical Center in Bethesda. No impact on the 2026 full-year forecast.","jir_og_title":"\u3010SymBio Pharmaceuticals\u3011First patient enrolled in PML clinical trial","jir_og_description":"Under the NIH\/NINDS CRADA, enrollment of the first patient in the IV BCV clinical trial targeting PML has been completed. Development in the neurodegenerative disease area will continue.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60012,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-62324","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Completion of Patient Enrollment (FPI) in NIH-led Clinical Trial of IV BCV for Progressive Multifocal Leukoencephalopathy - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/\",\"name\":\"Completion of Patient Enrollment (FPI) in NIH-led Clinical Trial of IV BCV for Progressive Multifocal Leukoencephalopathy - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-08T23:31:19+00:00\",\"dateModified\":\"2026-07-12T02:19:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Completion of Patient Enrollment (FPI) in NIH-led Clinical Trial of IV BCV for Progressive Multifocal Leukoencephalopathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Completion of Patient Enrollment (FPI) in NIH-led Clinical Trial of IV BCV for Progressive Multifocal Leukoencephalopathy - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/","url":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/","name":"Completion of Patient Enrollment (FPI) in NIH-led Clinical Trial of IV BCV for Progressive Multifocal Leukoencephalopathy - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-08T23:31:19+00:00","dateModified":"2026-07-12T02:19:09+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260609-01_wp_basic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Completion of Patient Enrollment (FPI) in NIH-led Clinical Trial of IV BCV for Progressive Multifocal Leukoencephalopathy"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"60012","title":"\u30b7\u30f3\u30d0\u30a4\u30aa\u88fd\u85ac(\u682a)","ticker":"4582"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/62324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=62324"}],"version-history":[{"count":1,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/62324\/revisions"}],"predecessor-version":[{"id":78818,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/62324\/revisions\/78818"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=62324"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=62324"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=62324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}